Therapeutic Response
EGFR Somatic variants status confers therapeutic sensitivity to Atezolizumab in combination with Bevacizumab, Carboplatin, and Paclitaxel in patients with Non-Small Cell Lung Cancer.
Statements
| Source and description |
|---|
EGFR Somatic variants status confers therapeutic sensitivity to Atezolizumab in combination with Bevacizumab, Carboplatin, and Paclitaxel in patients with Non-Small Cell Lung Cancer.
| Source and description |
|---|